SIG
IRWD icon

Stanford Investment Group’s Ironwood Pharmaceuticals IRWD Stock Holding History

Stanford Investment Group’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-31,137
Closed -$302K – 360
2015
Q4 		$302K Sell
31,137
-21,015
-40% -$203K 0.16% 44
2015
Q3 		$455K Hold
52,152
– – 0.33% 26
2015
Q2 		$527K Hold
52,152
– – 0.39% 23
2015
Q1 		$699K Hold
52,152
– – 0.56% 19
2014
Q4 		$669K Buy
+52,152
New +$597K 0.56% 20

Other funds holding IRWD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Stanford Investment Group's IRWD Position: Q1 2016 in Review

Stanford Investment Group sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2016, closing a stake of 31,137 shares — an estimated $302K sold.

Stanford Investment Group first reported a position in IRWD in Q4 2014 and held it in 5 quarters. The position peaked at $699K in Q1 2015. 136 funds tracked by Wall St. Rank hold IRWD as of Q1 2016.

  • Stanford Investment Group reported no remaining Ironwood Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Stanford Investment Group sold 31,137 Ironwood Pharmaceuticals shares in Q1 2016, an estimated $302K.
  • Stanford Investment Group first reported a position in Ironwood Pharmaceuticals in Q4 2014 and held it in 5 quarters.
  • Stanford Investment Group's Ironwood Pharmaceuticals position peaked at $699K in Q1 2015.
  • 136 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2016.

Based on Stanford Investment Group's 13F filing for Q1 2016, filed 10 Nov 2016.